Oct 19, 2025
3 min read
Corovirus vaccines have nothing to do with the virus that protects against the virus. The idea is to mobilize the immune system during cancer treatment to fight disease.
Covid vaccines may offer tantalizing benefits that have nothing to do with the virus they are intended to protect against: strengthening the immune system to better fight tumors during cancer treatment.
This is the new results that will be presented in Saberlin as the new convention of the Medical Prognostic Conference in Berlin.The research is still in the early manual stages — it has yet to be tested in a Phase 3 clinical trial — but experts say it's promising.
Director of Guvma Certification of Guv Vita Education Department of Guv Vita Education Department of Guv Vet and Hematology Department said.
Researchers found that among cancer patients treated with immunotherapy, those who received the mRNA Covid vaccine within 100 days before starting treatment lived longer.
Only 20% of cancer patients with immunotherapy respond to the drug by attacking the cancer cells with the human immune system.Finding a way to increase the effectiveness of immunotherapy has been sought by researchers for many years.
Typically, immune stimulation tactics employed in the past have done too little to activate the immune system or have done too much, triggering an overactive response that can harm the body.There is a possibility of mRNA Covid vaccines being in the Goldilocks zone.
Dapugan that was strong - strong are strong and it can be like this.
The Research to: D.Aadam Grippin, Senior Game in Texas to Texas School Texas School
In a study presented Sunday, Grippin and his coauthors looked back at the survival rates of people over 100 years old who received Mr.2023.
There was a median survival for the group - when half the treatment was still alive - almost twice as long as for those who received the vaccine: about three years compared to about 1.5 years.
The researchers also compared the survival rates of a small group of patients who received immunotherapy for metastatic melanoma.Forty-three of them received the mRNA COVID vaccine;167 did not.For those who did not receive the vaccine, the average survival rate was just over two years.Those who were vaccinated before treatment remained the same after more than three years of follow-up, with their average survival not reaching that point.
In additional experiments in mice, the researchers obtained a response that they believe is consistent with how vaccines work in humans.
"It turns the immune system against tumors," Grippin said.
Creating a biton
Vaccines using mRNA are a promising area of cancer research.Scientists are developing vaccines for a person's unique tumors and targeting genes found in certain types of cancer, including pancreatic.(This development comes as the Trump administration canceled half a billion dollars in funding for mRNA vaccine research for infectious diseases)
If the later Crippen trial confirms the earlier findings, MRNA V could be included in vaccine and cancer research.
Immunotherapy uses drugs to increase the immune system's ability to fight cancer.
One part of the new research found in mice that the Covid mRNA vaccine appeared to make the immune system more sensitive to recognizing tumor threats by activating dendritic cells, a type of white blood cell.When dendritic cells detect the threat, they become a kind of beacon that leads T cells to attack the perceived invader.However, not everyone has T cells naturally capable of fighting tumors that are, which is why scientists believe immunotherapy works in some cancer patients who receive it.In these people, the immune system recognizes cancer cells as a threat, but their own T cells cannot stop the tumors from growing.
"It's random chance whether you have these cells or not," said Jeff Kohler, professor of RNA biology and therapeutics at Johns Hopkins Medicine, who was not involved in the research.
Getting the mRNA covid vaccine doesn't change whether a person has the specific T cells needed to fight their tumor, but it does appear to make dendritic cells more likely to find the problematic tumor and direct the T cells that a person has.If these cells are programmed to be able to kill tumor cells, then using a target-enhancing mRNA vaccine before a person starts immunotherapy can help strengthen their immune system, helping the cancer treatment work better.
Coller says that mRNA technology may be the best tool for expanding that response because every cell in the body already contains mRNA.
"We're really taking advantage of natural processes that your body already knows how to respond to," he says."You use your body's natural systems to fight tumors."
Dougan said other factors may have accounted for better survival among people who were vaccinated before immunotherapy treatment.For example, a Covid infection may have weakened an unvaccinated person's body and hindered their ability to fight cancer cells.In the past, early studies like this showed promising results that fell flat in later studies.
"We've already been fooled by retrospective studies," he said.
Gripping agreed that the findings warrant further study.
"These data are exciting, but all these results need to be validated in phase 3 clinical trials to determine whether we should use these vaccines in patients," he said.
